Parabilis Medicines, Inc. (PBLS)

37.50 +0.56 (+1.53%) USD  |  NASDAQ  |  Sep 22, 12:51
More

Parabilis Medicines Shareholders Equity (Quarterly) : 1.048B for June 30, 2026

Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for PBLS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2026. Start Trial.
Date Value
June 30, 2026 1.048B
Date Value
March 31, 2026 244.22M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
Arrowhead Pharmaceuticals, Inc. 465.53M
Oncolytics Biotech, Inc. -6.167M
Sangamo Therapeutics, Inc. -18.96M
Sarepta Therapeutics, Inc. 1.528B
Anixa Biosciences, Inc. 14.47M

Shareholders Equity (Quarterly) Related Metrics

Total Assets (Quarterly) 1.175B
Total Liabilities (Quarterly) 127.53M
Debt to Equity Ratio 0.0453
Current Ratio 17.91
Net Debt Paydown Yield -0.22%